Read by QxMD icon Read


Loretta Fala
No abstract text is available yet for this article.
March 2016: American Health & Drug Benefits
Renata Baronaite Hansen, Arthur Kavanaugh
INTRODUCTION: Secukinumab (Cosentyx) is an interleukin-17A (IL-17A) inhibitor administered subcutaneously. Through 2016, it had received approval in a number of countries, including the USA, Japan and in the EU for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). AREAS COVERED: This review addresses the mechanism of action, efficacy and safety of secukinumab observed in clinical studies of patients with PsA. Data from recent studies of secukinumab in psoriasis, PsA and AS are included...
October 2016: Expert Review of Clinical Immunology
Marije I Koenders, Wim B van den Berg
Rheumatic disease is not a single disorder, but a group of more than 100 diseases that affect joints, connective tissues, and/or internal organs. Although rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis, and ankylosing spondylitis (AS) differ in their pathogenesis and clinical presentation, the treatment of these inflammatory disorders overlaps. Non-steroid anti-inflammatory drugs are used to reduce pain and inflammation. Additional disease-modifying anti-rheumatic drugs are prescribed to slowdown disease progression, and is in RA more frequently and effectively applied than in AS...
2016: Drug Design, Development and Therapy
Matt Shirley, Lesley J Scott
Secukinumab (Cosentyx(®)) is a high affinity, human monoclonal antibody targeted against interleukin (IL)-17A. It is the first-in-class anti-IL-17 agent, initially approved for the treatment of plaque psoriasis, and more recently for the treatment of ankylosing spondylitis and psoriatic arthritis. This article reviews the therapeutic efficacy of subcutaneous secukinumab in the treatment of psoriatic arthritis, as well as discussing the tolerability and pharmacological properties of the drug. Phase III clinical trial data demonstrated that, compared with placebo, subcutaneous secukinumab was efficacious in improving the signs and symptoms of psoriatic arthritis in patients with active disease despite previous treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or disease-modifying anti-rheumatic drugs (DMARDs)...
July 2016: Drugs
Hannah A Blair, Sohita Dhillon
Secukinumab (Cosentyx(®)) is a fully human monoclonal antibody against the proinflammatory cytokine interleukin-17A. It is the first drug in its class to be approved for use in patients with active ankylosing spondylitis (AS). This article reviews the efficacy and tolerability of secukinumab in this indication and briefly summarizes its pharmacology. In ongoing phase III trials, 16 weeks' treatment with subcutaneous secukinumab 150 mg was effective in terms of improving the clinical signs and symptoms of disease and health-related quality of life in patients with AS, with these improvements maintained during longer-term (up to 2 years) treatment...
July 2016: Drugs
(no author information available yet)
No abstract text is available yet for this article.
June 6, 2016: Medical Letter on Drugs and Therapeutics
Aditya K Gupta, Kelly A Foley, William Abramovits
No abstract text is available yet for this article.
July 2015: Skinmed
Michael Roman, Vandana K Madkan, Melvin W Chiu
Secukinumab (Cosentyx™) is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. It is known that this cytokine is elevated in lesions of psoriasis. Interleukins in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. As a monoclonal antibody immune modulator, secukinumab exhibits the expected pharmacokinetic properties of slow subcutaneous absorption, low clearance, and long half-life, although formal studies examining the impact of impaired hepatic or renal function on the overall pharmacokinetic profile have not been conducted...
2015: Therapeutics and Clinical Risk Management
Olga M Klibanov, Diep Phan, Kelli Ferguson
This article highlights important prescribing information for some drugs that received FDA approval within the past year. These include: atazanavir and cobicistat (Evotaz®), ceftazidime and avibactam (Avycaz®), edoxaban (Savaysa®), ivabradine (Corlanor®), liraglutide (rDNA origin) injection (Saxenda®), perindopril arginine and amlodipine besylate (Prestalia®), and secukinumab (Cosentyx®) subcutaneous injection.
December 12, 2015: Nurse Practitioner
Karly P Garnock-Jones
Secukinumab (Cosentyx™) is a fully human monoclonal immunoglobulin G1κ antibody targeting human interleukin-17A, an important cytokine in the pathogenesis of psoriasis. Secukinumab, as well as being first in its drug class, is the first biologic treatment to be approved in the EU for the first-line systemic treatment of moderate to severe plaque psoriasis. This article reviews the pharmacologic properties of secukinumab and its clinical efficacy and tolerability in adult patients with moderate to severe plaque psoriasis...
August 2015: American Journal of Clinical Dermatology
Kunj Gohil
Palbociclib (Ibrance) for breast cancer, secukinumab (Cosentyx) for plaque psoriasis, meningococcal group B vaccine (Bexsero) to help prevent meningitis, and lenvatinib (Lenvima) for differentiated thyroid cancer.
April 2015: P & T: a Peer-reviewed Journal for Formulary Management
(no author information available yet)
No abstract text is available yet for this article.
March 30, 2015: Medical Letter on Drugs and Therapeutics
Mark Sanford, Kate McKeage
Secukinumab (Cosentyx™) is a fully human monoclonal antibody against interleukin-17A, formulated for intravenous and subcutaneous administration. It received its first global approval in Japan on 26 December 2014 for the treatment of psoriasis and psoriatic arthritis in adults who are not adequately responding to systemic therapies (except for biologic agents). In the USA and the EU, secukinumab was approved in early 2015 for the treatment of patients with moderate-to-severe plaque psoriasis. Secukinumab is also being investigated in patients with ankylosing spondylitis and rheumatoid arthritis...
February 2015: Drugs
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"